HEALTH● LOWAug 19 · Aug 19, 2026, 12:54 PM
Teva gets FDA priority review for Tourette syndrome therapy
Seeking Alpha Tech
Teva Pharmaceuticals has received priority review status from the FDA for its new therapy designed to treat Tourette syndrome, potentially accelerating its approval process.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH18m agoSAT Hospital in Keralam rejects charges of ‘clinical trial drugs’ given to SMA-afflicted childrenThe HinduHEALTH18m agoNile University of Nigeria Inducts 75 New Medical Doctors at 5th MBBS Attestation CeremonyVanguard NigeriaHEALTH19m agoEbola: Idris directs agencies to intensify public enlightenmentVanguard NigeriaHEALTH30m agoAdekunle Gold, Pesa commit $20,000 to sickle cell organisationsPremium Times